Education
About Us
Working with TipRanks
Follow Us
Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
BOLD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.42 - $14.18
Previous CloseN/A
Volume5.57K
Average Volume (3M)88.78K
Market Cap
$33.67M
Enterprise Value-$39.86M
Total Cash (Recent Filing)$36.36M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta2.93
Next Earnings
May 19, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding22,300,043
10 Day Avg. Volume53,606
30 Day Avg. Volume88,778
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.59
Forecast
1Y Price Target
$15.00Price Target Upside893.38% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Boundless Bio Inc. News
PremiumCompany Announcements
Boundless Bio’s 2024 Financial Results and Strategic ProgressPremiumCompany Announcements
Boundless Bio Shifts Focus and Restructures Leadership Team---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentThe company remains on track for the other pipeline assets, BBI-355 (CHK1) and the third ecDNA therapy program that will be focused on kinesin and ecDNA segregation.
Safety ProfileNo new safety signals have been observed to date in the POTENTIATE trial, indicating a favorable safety profile for the ongoing research.
Bears Say
Leadership ChangesThe company announced leadership changes, including a CMO transition and the departure of the CBO.
Product DiscontinuationBOLD announced discontinuation of BBI-825 (RNR inhibitor) after the Part 1 portion of the Ph 1/2 STARMAP trial demonstrated a lack of dose-proportional exposure in the pharmacokinetic data.
---
Ownership Overview
22.65% Insiders
8.32% Mutual Funds
27.71% Other Institutional Investors
36.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLD FAQ
What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $1.42 and its highest was $14.18 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Boundless Bio Inc.’s market cap is $33.67M.
When is Boundless Bio Inc.’s upcoming earnings report date?
Boundless Bio Inc.’s upcoming earnings report date is May 19, 2025 which is in 47 days.
How were Boundless Bio Inc.’s earnings last quarter?
Boundless Bio Inc. released its earnings results on Mar 27, 2025. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.757 by $0.017.
Is Boundless Bio Inc. overvalued?
According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate is -0.75.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 22,300,043 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Boundless Bio Inc. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.757. Following the earnings report the stock price went down -0.658%.
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Currently, no hedge funds are holding shares in BOLD
---
Boundless Bio Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (893.38% Upside)
$15.00 (893.38% Upside)
Blogger Sentiment
Bullish
BOLD Sentiment 100%
Sector Average 76%
Sector Average 76%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.40%
12-Months-Change
Fundamentals
Return on Equity
-554.86%
Trailing 12-Months
Asset Growth
58.91%
Trailing 12-Months
Company Description
Boundless Bio Inc.
Boundless Bio Inc. (BOLD) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in targeting extrachromosomal DNA (ecDNA) in cancer cells, aiming to address genomic amplification and improve treatment outcomes. Boundless Bio operates within the biopharmaceutical sector, leveraging cutting-edge research to create products that can potentially transform cancer care.
---
BOLD Stock 12 Month Forecast
Average Price Target
$15.00
▲(893.38% Upside)
Technical Analysis
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering BOLD
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-62.93%
reiterated a buy rating 6 days ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -62.93% per trade.
---